MX2017016955A - Resveratrol and cisplatin compositions for inhibiting the proliferation of cancer cells resistant to cisplatin treatment. - Google Patents

Resveratrol and cisplatin compositions for inhibiting the proliferation of cancer cells resistant to cisplatin treatment.

Info

Publication number
MX2017016955A
MX2017016955A MX2017016955A MX2017016955A MX2017016955A MX 2017016955 A MX2017016955 A MX 2017016955A MX 2017016955 A MX2017016955 A MX 2017016955A MX 2017016955 A MX2017016955 A MX 2017016955A MX 2017016955 A MX2017016955 A MX 2017016955A
Authority
MX
Mexico
Prior art keywords
cisplatin
treatment
compositions
resveratrol
proliferation
Prior art date
Application number
MX2017016955A
Other languages
Spanish (es)
Inventor
García Carrancá Alejandro
Gariglio Vidal Patricio
León Galicia Ismael
RUIZ RAMIREZ Graciela
García Villa Enrique
ÁLVAREZ RÍOS Elizabeth
Violante Mota Fernando
Original Assignee
Centro De Investig Y De Estudios Avanzados Del I P N
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro De Investig Y De Estudios Avanzados Del I P N filed Critical Centro De Investig Y De Estudios Avanzados Del I P N
Priority to MX2017016955A priority Critical patent/MX2017016955A/en
Publication of MX2017016955A publication Critical patent/MX2017016955A/en

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention discloses pharmaceutical compositions comprising resveratrol and cisplatin, useful for inhibiting the proliferation of cancer cells resistant to cisplatin treatment. Said compositions are capable of reversing the resistance to cisplatin (or its analogs) observed in the treatment of various cancers, so they are ideal for the treatment where such resistance is present. Also, it addresses the problem of resistance or lack of response developed to the action of chemotherapeutic agents, specifically those that occur in breast cancer of various types. Further, due to the low concentrations of the active ingredients of said compositions, the adverse effects observed by the administration of high concentrations of cisplatin during the treatment of various cancers are diminished or eliminated.
MX2017016955A 2017-12-20 2017-12-20 Resveratrol and cisplatin compositions for inhibiting the proliferation of cancer cells resistant to cisplatin treatment. MX2017016955A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MX2017016955A MX2017016955A (en) 2017-12-20 2017-12-20 Resveratrol and cisplatin compositions for inhibiting the proliferation of cancer cells resistant to cisplatin treatment.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2017016955A MX2017016955A (en) 2017-12-20 2017-12-20 Resveratrol and cisplatin compositions for inhibiting the proliferation of cancer cells resistant to cisplatin treatment.

Publications (1)

Publication Number Publication Date
MX2017016955A true MX2017016955A (en) 2019-06-21

Family

ID=67808971

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017016955A MX2017016955A (en) 2017-12-20 2017-12-20 Resveratrol and cisplatin compositions for inhibiting the proliferation of cancer cells resistant to cisplatin treatment.

Country Status (1)

Country Link
MX (1) MX2017016955A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114504568A (en) * 2022-04-21 2022-05-17 深圳市人民医院 Application of small molecule compound in preparing medicine for inducing immunogenic cell death

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114504568A (en) * 2022-04-21 2022-05-17 深圳市人民医院 Application of small molecule compound in preparing medicine for inducing immunogenic cell death

Similar Documents

Publication Publication Date Title
PH12018500284A1 (en) 5-bromo-2,6-di-(1h-pyrazol-1-yl)pyrimidin-4-amine for use in the treatment of cancer
PH12018502535A1 (en) Substituted carbonucleoside derivatives useful as anticancer agents
PH12017501413A1 (en) Substituted nucleoside derivatives useful as anticancer agents
PH12017500367A1 (en) Compounds that inhibit mcl-1 protein
PH12020550051A1 (en) Glp-1 compositions and uses thereof
MY188749A (en) Compositions comprising a combination of nivolumab and ipilimumab
MX2018006217A (en) Apelin receptor agonists and methods of use.
PH12018500987A1 (en) Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
MX2021001884A (en) Pyrazine compounds and uses thereof.
PH12021550779A1 (en) Sting agonistic compound
MX2021002998A (en) Triazolo-pyrimidine compounds and uses thereof.
EA201691590A1 (en) BENZIMIDAZOL-2-AMINES AS MIDHI INHIBITORS
MX2018004344A (en) 2,4-dihydroxy-nicotinamides as apj agonists.
MX2018011100A (en) Combinations of lsd1 inhibitors for the treatment of hematological malignancies.
MX2019003363A (en) Pharmaceutical compositions for use in the therapy of blepharitis.
MX2020001404A (en) Dihydrooxadiazinones.
TW201613594A (en) Pharmaceutical composition containing diamino heteroring carboxamide derivatives
WO2018044369A3 (en) Triple drug combination (metformin, simvastatin, digoxin) for targeted treatment of pancreatic cancer
JOP20210318A1 (en) SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE
EA032654B9 (en) [1,2,4]TRIAZOLO[4,3-b]PYRIDAZINES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES
MX2017016955A (en) Resveratrol and cisplatin compositions for inhibiting the proliferation of cancer cells resistant to cisplatin treatment.
EA201700286A1 (en) MACROMOLECULAR COMPLEXES OF TRANSITIONAL METAL FOR CANCER TREATMENT AND METHOD OF OBTAINING THEM
EA201792676A1 (en) JAK1 INHIBITORS
EA032385B9 (en) Pharmaceutical composition for treating gastrointestinal diseases
MX2019003374A (en) Combined composition for preventing or treating cancer comprising a benzophenone thiazole derivatives as a vda and topoisomerase inhibitor.